Chr Hansen announces acquisition of Jennewein
Jennewein’s products will have strong functional synergies with our probiotic bacteria, such as LGG® and BB-12® and combining the companies will create an even stronger competitive advantage. Image credit: Chr Hansen
Chr Hansen Holding A/S (Chr. Hansen) has entered into an agreement to acquire all of the shares of Jennewein Biotechnologie GmbH (Jennewein), a leading player in the Human Milk Oligosaccharides (HMO) market.
The acquisition is fully in line with Chr Hansen’s 2025 Strategy of pursuing bolt-on acquisitions that extend and strengthen its microbial and fermentation technology platforms.
Mauricio Graber, CEO of Chr Hansen, said: “I am truly excited that we have reached an agreement to acquire Jennewein. The fast-growing HMO market is a new space that we have been following with strong interest for some years. In truth, we are making a long-term investment and commitment to HMOs, which I am convinced will bring long-term value creation to our shareholders. Given the addressable market and the expected growth rates, this is now our 5th strategic lighthouse and will be accretive to our organic growth beyond 2020/21. HMOs also fit perfectly with our purpose to, ‘Grow a better world. Naturally’, as these are some of nature’s most intricate nutritional components for the most precious and vulnerable – newborn infants and young children.
“For us, Jennewein is a strong fit to our microbial portfolio, as its fermentation platform is also scalable and offers good long-term margin potential as volumes increase. Jennewein is a leader in the HMO industry with a superior product offering and IP portfolio, and we believe the company holds a leading position in this relatively new and very exciting market. Jennewein’s products will have strong functional synergies with our probiotic bacteria, such as LGG and BB-12 and combining the companies will create an even stronger competitive advantage. Furthermore, we believe that the very talented employees of Jennewein will be a strong cultural fit to Chr. Hansen,” concluded Graber.
Dr Stefan Jennewein, founder and CEO of Jennewein, said: “Today, we are starting a new chapter in the pre- and synbiotic market by combining the strengths of Chr Hansen and Jennewein Biotechnologie. 15 years ago, Jennewein started with the ambition to make human milk oligosaccharides available for all infants. Today, HMOs have become a must-have for all premium infant formula. Whereas initially we were very much intrigued by the anti-infective effects of HMOs, in particular against human pathogenic viruses, today it is clear that even more beneficial effects can be expected from the combination of HMOs with probiotics. Thus, Chr Hansen is the perfect match for Jennewein to bring the HMO story to the next level.”
